Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11942317 | 0.83 | NOTUM (0.38) | NOTUMKDM1A | |
| SCHEMBL15218262 | 0.80 | PTGDR2 (0.36) | — | |
| SCHEMBL24012991 | 0.75 | HDAC1 (0.34) | — | |
| SCHEMBL30626575 | 0.75 | KDM1A (0.43) | KIF11KDM1APTPN7DUSP3 | |
| SCHEMBL20196946 | 0.75 | KDM1A (0.43) | KIF11KDM1APTPN7DUSP3 | |
| SCHEMBL26019034 | 0.74 | NOTUM (0.33) | NOTUMADRB2KIF11KDM1A | |
| SCHEMBL21141922 | 0.74 | KIF11 (0.35) | NOTUMADRB2KIF11KDM1APTPN7 | |
| SCHEMBL12535526 | 0.74 | CYP3A4 (0.39) | — | |
| SCHEMBL13550103 | 0.74 | AR (0.35) | NOTUMKDM1A | |
| SCHEMBL31698223 | 0.74 | ADRB2 (0.38) | NOTUMADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | NOTUM 1026/4885ADRB2 57/4885KIF11 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.